Free CME from PeerView


Continuing Nursing Education (CNE) Activities

Meghan C. Thompson, MD
Credits: 0.75 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

Start

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

Media: Enduring Material
Activity Release Date: April 5, 2024
Activity Expiration Date: April 4, 2025
Time to Complete Activity: 45 minutes

Activity Description

Enhance your expertise in developing modern sequential treatment with BTK inhibitor (BTKi) options for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)! This educational activity, led by a CLL care expert, delves into the critical distinctions between covalent and non-covalent BTK inhibitors, explores strategic approaches to prognostic factor testing to inform treatment selection and planning, and provides guidance on the safe sequential use of BTKi in patients progressing on treatment. Throughout, question-based assessments will offer you a customized learning experience designed to build skills for the effective management of patients with R/R CLL.

This program is also part of a larger curriculum developed in collaboration with CLL Society. For more information about useful point-of-care tools and educational resources that can be shared with your patients and used to encourage collaborative care, please view other components of this series: PeerView.com/HGE. Collected CLL Society resources can be found here: PeerView.com/onDemand/programs/150209250-2/downloads/PVI_practiceaids_HGE.pdf.

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology physician specialists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
  • Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
  • Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
  • Employ team-based approaches to address practical aspects of CLL management when using BTKi, including coordinating care, formulary planning, educating patients, dosing, and managing treatment-related AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to institution.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-046-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 4/4/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

Media: Enduring Material
Activity Release Date: April 5, 2024
Activity Expiration Date: April 4, 2025
Time to Complete Activity: 45 minutes

Activity Description

Enhance your expertise in developing modern sequential treatment with BTK inhibitor (BTKi) options for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)! This educational activity, led by a CLL care expert, delves into the critical distinctions between covalent and non-covalent BTK inhibitors, explores strategic approaches to prognostic factor testing to inform treatment selection and planning, and provides guidance on the safe sequential use of BTKi in patients progressing on treatment. Throughout, question-based assessments will offer you a customized learning experience designed to build skills for the effective management of patients with R/R CLL.

This program is also part of a larger curriculum developed in collaboration with CLL Society. For more information about useful point-of-care tools and educational resources that can be shared with your patients and used to encourage collaborative care, please view other components of this series: PeerView.com/HGE. Collected CLL Society resources can be found here: PeerView.com/onDemand/programs/150209250-2/downloads/PVI_practiceaids_HGE.pdf.

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology physician specialists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
  • Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
  • Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
  • Employ team-based approaches to address practical aspects of CLL management when using BTKi, including coordinating care, formulary planning, educating patients, dosing, and managing treatment-related AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to institution.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-046-H01-P
Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 4/4/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

April 05, 2024
Roy F. Chemaly, MD, MPH, FIDSA, FACP/Genovefa Papanicolaou, MD, FIDSA, Fellow ASCT
Credits: 1.0 CME / NCPD
PVI, PeerView Institute for Medical Education
Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents

Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents

Start

Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents

Activity Description and Educational Objectives

Cytomegalovirus (CMV) remains a challenging complication of hematopoietic cell transplant (HCT), with many patients experiencing resistant/refractory (R/R) infection or treatment intolerance after standard frontline treatment. Modern, newly developed antiviral options have the potential to address these challenges and offer clinicians a potent tool for use against persistent CMV infections. Newer antivirals also have the potential to enhance personalized care for patients with hard-to-treat CMV infection and overcome treatment resistance in the post-HCT setting.

In this activity recorded at the 2024 Tandem Meetings, experts assess the evidence behind modern antiviral agents as a foundation for case-based demonstrations of how to combat CMV in real-world practice. Throughout, the panelists will share strategies for treating R/R infections, overcoming treatment intolerance, and caring for patients whose post-HCT goals have been compromised by persistent CMV. Learn how cracking down on CMV can contribute to successful post-transplant outcomes!

Upon completion of this activity, participants should be better able to:

  • Discuss the efficacy and safety data and biologic rationale supporting the integration of newer antiviral agents into modern treatment plans for resistant/refractory cytomegalovirus (CMV) infections in the post-HCT setting
  • Develop team-based, personalized treatment plans that include newer antiviral agents along the continuum of post-HCT CMV infection management, including in the settings of resistant or refractory disease
  • Implement collaborative protocols to address practical aspects of antiviral care when using newer antiviral strategies, including monitoring, patient/caregiver education, adherence, and adverse event management

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the management of post-transplant CMV.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 26, 2024 - March 25, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chairs & Presenters
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor and Chair
G. P. Bodey, Sr. Distinguished Professorship in Infectious Diseases
Director, Clinical Virology Research
Department of Infectious Disease, Infection Control and Employee Health
The University of Texas MD Anderson Cancer Center
Houston, Texas

Roy F. Chemaly, MD, MPH, FIDSA, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ADMA Biologics; AiCuris; Ansun BioPharma; Astellas Pharma Inc.; F. Hoffmann-La Roche AG; Karius; Merck & Co., Inc./MSD; Moderna, Inc.; Oxford Immunotec; Shionogi Inc.; Tether; and The Takeda Pharmaceutical Company Limited.
Grant/Research Support from AiCuris; Ansun BioPharma; Eurofins Viracor; Genentech, Inc.; Karius; Merck & Co., Inc./MSD; Oxford Immunotec; and The Takeda Pharmaceutical Company Limited. Research funds paid to institution.

Genovefa Papanicolaou, MD, FIDSA, Fellow ASCT
Member and Attending Physician, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medicine
New York, New York

Genovefa Papanicolaou, MD, FIDSA, Fellow ASCT, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AiCuris; Eurofins Viracor, LLC; Merck & Co., Inc./MSD; and The Takeda Pharmaceutical Company Limited. Research funds paid to institution.
Other Financial or Material Support as Consultant and/or Advisor and/or Data Safety Monitoring Board for AlloVir; Merck & Co., Inc./MSD; Symbio, Inc.; and Takeda Pharmaceutical Company Limited.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents

Activity Description and Educational Objectives

Cytomegalovirus (CMV) remains a challenging complication of hematopoietic cell transplant (HCT), with many patients experiencing resistant/refractory (R/R) infection or treatment intolerance after standard frontline treatment. Modern, newly developed antiviral options have the potential to address these challenges and offer clinicians a potent tool for use against persistent CMV infections. Newer antivirals also have the potential to enhance personalized care for patients with hard-to-treat CMV infection and overcome treatment resistance in the post-HCT setting.

In this activity recorded at the 2024 Tandem Meetings, experts assess the evidence behind modern antiviral agents as a foundation for case-based demonstrations of how to combat CMV in real-world practice. Throughout, the panelists will share strategies for treating R/R infections, overcoming treatment intolerance, and caring for patients whose post-HCT goals have been compromised by persistent CMV. Learn how cracking down on CMV can contribute to successful post-transplant outcomes!

Upon completion of this activity, participants should be better able to:

  • Discuss the efficacy and safety data and biologic rationale supporting the integration of newer antiviral agents into modern treatment plans for resistant/refractory cytomegalovirus (CMV) infections in the post-HCT setting
  • Develop team-based, personalized treatment plans that include newer antiviral agents along the continuum of post-HCT CMV infection management, including in the settings of resistant or refractory disease
  • Implement collaborative protocols to address practical aspects of antiviral care when using newer antiviral strategies, including monitoring, patient/caregiver education, adherence, and adverse event management

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the management of post-transplant CMV.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 26, 2024 - March 25, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chairs & Presenters
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor and Chair
G. P. Bodey, Sr. Distinguished Professorship in Infectious Diseases
Director, Clinical Virology Research
Department of Infectious Disease, Infection Control and Employee Health
The University of Texas MD Anderson Cancer Center
Houston, Texas

Roy F. Chemaly, MD, MPH, FIDSA, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ADMA Biologics; AiCuris; Ansun BioPharma; Astellas Pharma Inc.; F. Hoffmann-La Roche AG; Karius; Merck & Co., Inc./MSD; Moderna, Inc.; Oxford Immunotec; Shionogi Inc.; Tether; and The Takeda Pharmaceutical Company Limited.
Grant/Research Support from AiCuris; Ansun BioPharma; Eurofins Viracor; Genentech, Inc.; Karius; Merck & Co., Inc./MSD; Oxford Immunotec; and The Takeda Pharmaceutical Company Limited. Research funds paid to institution.

Genovefa Papanicolaou, MD, FIDSA, Fellow ASCT
Member and Attending Physician, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medicine
New York, New York

Genovefa Papanicolaou, MD, FIDSA, Fellow ASCT, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AiCuris; Eurofins Viracor, LLC; Merck & Co., Inc./MSD; and The Takeda Pharmaceutical Company Limited. Research funds paid to institution.
Other Financial or Material Support as Consultant and/or Advisor and/or Data Safety Monitoring Board for AlloVir; Merck & Co., Inc./MSD; Symbio, Inc.; and Takeda Pharmaceutical Company Limited.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 26, 2024
Sergio A. Giralt, MD, FACP/Brittany Knick Ragon, MD
Credits: 1.0 CME / NCPD
The Medical College of Wisconsin
Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies

Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies

Start

Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies

Activity Description and Educational Objectives

While hematopoietic cell transplantation (HCT) has remained a constant in acute myeloid leukemia (AML) care, newer cytotoxic platforms, next-generation FLT3i, and emerging immune-based approaches are displacing conventional strategies as more effective pre-transplant and post-HCT maintenance options, allowing clinicians to develop a more personalized approach to AML management and reinforce and deepen the benefits achieved with HCT.

In this activity, join the experts and learn how to enhance outcomes by using modern therapies in conjunction with HCT by viewing case-based guidance on “bridging” to and from transplant with newer therapeutics, including as induction/consolidation with modern targeted and cytotoxic platforms, advances with post-HCT maintenance, and the role of radioimmunoconjugates as pre-HCT conditioning. This is an excellent opportunity to stay abreast of the latest developments in AML care and learn what new science will mean for delivering and enhancing the efficacy of HCT for eligible patients.

Upon completion of this activity, participants should be better able to:

  • Cite evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, radioimmunoconjugates, and immunotherapy as pre-transplant strategies in different AML settings
  • Select pre-HCT therapy for patients with ND or R/R AML based on targetable mutations, transplant candidacy, functional status, treatment setting, or disease subtype
  • Manage optimized dosing, response monitoring, and safety management consideration when using modern therapeutic platforms in the AML setting

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the care of patients with AML.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 26, 2024 - March 25, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Chief Medical Officer, MSK Direct
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, New York

Sergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Johnson & Johnson, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Johnson & Johnson, Inc.; Miltenyi Biotec; Sanofi; and Takeda Pharmaceutical Company Limited.

Co-Chair & Presenter
Brittany Knick Ragon, MD
Division of Leukemia, Department of Hematologic Oncology and Blood Disorders
Director of Hematology Operations
Levine Cancer Institute, Atrium Health
Clinical Assistant Professor, Department of Internal Medicine
Wake Forest University School of Medicine
Charlotte, North Carolina

Brittany Knick Ragon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas; Genentech, Inc.; and Pfizer.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Support

This activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies

Activity Description and Educational Objectives

While hematopoietic cell transplantation (HCT) has remained a constant in acute myeloid leukemia (AML) care, newer cytotoxic platforms, next-generation FLT3i, and emerging immune-based approaches are displacing conventional strategies as more effective pre-transplant and post-HCT maintenance options, allowing clinicians to develop a more personalized approach to AML management and reinforce and deepen the benefits achieved with HCT.

In this activity, join the experts and learn how to enhance outcomes by using modern therapies in conjunction with HCT by viewing case-based guidance on “bridging” to and from transplant with newer therapeutics, including as induction/consolidation with modern targeted and cytotoxic platforms, advances with post-HCT maintenance, and the role of radioimmunoconjugates as pre-HCT conditioning. This is an excellent opportunity to stay abreast of the latest developments in AML care and learn what new science will mean for delivering and enhancing the efficacy of HCT for eligible patients.

Upon completion of this activity, participants should be better able to:

  • Cite evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, radioimmunoconjugates, and immunotherapy as pre-transplant strategies in different AML settings
  • Select pre-HCT therapy for patients with ND or R/R AML based on targetable mutations, transplant candidacy, functional status, treatment setting, or disease subtype
  • Manage optimized dosing, response monitoring, and safety management consideration when using modern therapeutic platforms in the AML setting

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the care of patients with AML.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 26, 2024 - March 25, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Chief Medical Officer, MSK Direct
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, New York

Sergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Johnson & Johnson, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Johnson & Johnson, Inc.; Miltenyi Biotec; Sanofi; and Takeda Pharmaceutical Company Limited.

Co-Chair & Presenter
Brittany Knick Ragon, MD
Division of Leukemia, Department of Hematologic Oncology and Blood Disorders
Director of Hematology Operations
Levine Cancer Institute, Atrium Health
Clinical Assistant Professor, Department of Internal Medicine
Wake Forest University School of Medicine
Charlotte, North Carolina

Brittany Knick Ragon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas; Genentech, Inc.; and Pfizer.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Support

This activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 26, 2024
Javier Morales, MD, FACP, FACE
Credits: 0.5 CME / NCPD / AAPA
PVI, PeerView Institute for Medical Education
Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

Start

       

       
       

Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal


       

Media: Enduring Material
Activity Release Date: March 26, 2024
Activity Expiration Date: March 25, 2025
Time to Complete Activity: 30 minutes

Activity Description

Type 2 diabetes mellitus (T2DM) is a common, yet highly treatable progressive disease. Prompt therapy escalation is critical to contemporary management of people with T2DM (PwT2DM) as this correlates with improved long-term outcomes. Despite evidence-based guidelines recommending treatment intensification if glycemic goals are not achieved within three months, less than 50% of PwT2DM are managed appropriately. Further, outcomes for PwT2DM can also be significantly improved with weight loss, and current guidelines recommend PwT2DM lose weight and maintain weight loss. Yet, this is rarely achieved and the significance of modest weight loss is often underestimated, despite its impact on overall and long-term health outcomes. What are our next steps as primary care professionals?

In this activity, an expert utilizes simulated patient videos—thanks to a talented actor from the University of Delaware’s Healthcare Theatre Program—to present what primary care clinicians need to know to better serve PwT2DM in their practices. By the end, learners will have gained knowledge about how to intensify treatment for T2DM to minimize complications and gain the confidence needed to motivate patients using a personalized approach and shared decision-making.

Target Audience

This activity has been designed to meet the educational needs of US-based primary care professionals including physicians, NPs, PAs, and other clinicians involved in the management of T2DM.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Apply evidence-based guideline recommendations that prioritize weight loss as a treatment target in PwT2DM
  • Intensify treatment in a timely manner consistent with guideline recommendations and clinical evidence to help PwT2DM achieve personalized glycemic and weight loss goals
  • Utilize shared decision-making to develop individualized management plans for PwT2DM and overweight/obesity that consider their personal preferences, needs, and goals

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Javier Morales, MD, FACP, FACE
Clinical Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine
Hofstra Northwell Hempstead
Vice President
Advanced Internal Medicine Group, PC
East Hills, New York

Javier Morales, MD, FACP, FACE, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.
Speaker for Amgen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.

Faculty/Planner
John E. Anderson, MD
Past President
The Frist Clinic
Nashville, Tennessee

John E. Anderson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; Novo Nordisk Inc.; and Sanofi.
Speaker for Bayer HealthCare Pharmaceuticals Inc.; Lilly; Novo Nordisk Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


       
       
                   
                       
                       
                   
               
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Partners

Components of this activity have been developed in partnership with Healthcare Theatre from the University of Delaware.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/25/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   

   
   

       

       
       

Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal


       

Media: Enduring Material
Activity Release Date: March 26, 2024
Activity Expiration Date: March 25, 2025
Time to Complete Activity: 30 minutes

Activity Description

Type 2 diabetes mellitus (T2DM) is a common, yet highly treatable progressive disease. Prompt therapy escalation is critical to contemporary management of people with T2DM (PwT2DM) as this correlates with improved long-term outcomes. Despite evidence-based guidelines recommending treatment intensification if glycemic goals are not achieved within three months, less than 50% of PwT2DM are managed appropriately. Further, outcomes for PwT2DM can also be significantly improved with weight loss, and current guidelines recommend PwT2DM lose weight and maintain weight loss. Yet, this is rarely achieved and the significance of modest weight loss is often underestimated, despite its impact on overall and long-term health outcomes. What are our next steps as primary care professionals?

In this activity, an expert utilizes simulated patient videos—thanks to a talented actor from the University of Delaware’s Healthcare Theatre Program—to present what primary care clinicians need to know to better serve PwT2DM in their practices. By the end, learners will have gained knowledge about how to intensify treatment for T2DM to minimize complications and gain the confidence needed to motivate patients using a personalized approach and shared decision-making.

Target Audience

This activity has been designed to meet the educational needs of US-based primary care professionals including physicians, NPs, PAs, and other clinicians involved in the management of T2DM.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Apply evidence-based guideline recommendations that prioritize weight loss as a treatment target in PwT2DM
  • Intensify treatment in a timely manner consistent with guideline recommendations and clinical evidence to help PwT2DM achieve personalized glycemic and weight loss goals
  • Utilize shared decision-making to develop individualized management plans for PwT2DM and overweight/obesity that consider their personal preferences, needs, and goals

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Javier Morales, MD, FACP, FACE
Clinical Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine
Hofstra Northwell Hempstead
Vice President
Advanced Internal Medicine Group, PC
East Hills, New York

Javier Morales, MD, FACP, FACE, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.
Speaker for Amgen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.

Faculty/Planner
John E. Anderson, MD
Past President
The Frist Clinic
Nashville, Tennessee

John E. Anderson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; Novo Nordisk Inc.; and Sanofi.
Speaker for Bayer HealthCare Pharmaceuticals Inc.; Lilly; Novo Nordisk Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


       
       
                   
                       
                       
                   
               
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Partners

Components of this activity have been developed in partnership with Healthcare Theatre from the University of Delaware.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/25/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   

   
   
March 26, 2024
Krina Patel, MD, MSc/Hans Lee, MD
Credits: 1.0 CME / NCPD
PVI, PeerView Institute for Medical Education
Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

Start

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

Activity Description and Educational Objectives

Are you prepared to learn about BCMA strategies that will help you accelerate the achievement of deep and durable remissions in multiple myeloma (MM)? New evidence is pointing to the use of chimeric antigen receptor T-cell (CAR-T) constructs for MM in earlier lines of therapy, which will have implications for sequencing with other BCMA options. At the same time, “off-the-shelf” BCMA antibodies are transforming treatment choices in pretreated disease, offering clinicians another tool to achieve deep remissions. This activity features expert exchanges based around real-world patient cases that illustrate the central role of BCMA bispecifics and CAR-T therapy throughout the MM therapeutic journey. Each case conversation is linked to a short overview of the evidence supporting the experts’ treatment choices. Don’t miss this opportunity to “accelerate remission” and learn how to apply new science on BCMA platforms!

Upon completion of this activity, participants should be better able to:

  • Cite the safety and efficacy evidence supporting the use of established and emerging anti-BCMA platforms, including CAR-T and off-the-shelf antibody options, across several lines of therapy in MM
  • Integrate evidence-informed anti-BCMA platforms into customized sequential treatment plans for MM, including in early relapse and more heavily pretreated disease
  • Develop protocols to address practical aspects of anti-BCMA therapy, including planning for referral to specialized care, using appropriate bridging regimens, considering off-the-shelf antibody therapy, and understanding dosing and AE management

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the management of multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 22, 2024 - March 21, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Co-Chair & Presenter
Hans Lee, MD
Associate Professor, Department of Lymphoma/Myeloma
Director, Multiple Myeloma Clinical Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hans Lee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Support

This activity is supported through independent medical educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

Activity Description and Educational Objectives

Are you prepared to learn about BCMA strategies that will help you accelerate the achievement of deep and durable remissions in multiple myeloma (MM)? New evidence is pointing to the use of chimeric antigen receptor T-cell (CAR-T) constructs for MM in earlier lines of therapy, which will have implications for sequencing with other BCMA options. At the same time, “off-the-shelf” BCMA antibodies are transforming treatment choices in pretreated disease, offering clinicians another tool to achieve deep remissions. This activity features expert exchanges based around real-world patient cases that illustrate the central role of BCMA bispecifics and CAR-T therapy throughout the MM therapeutic journey. Each case conversation is linked to a short overview of the evidence supporting the experts’ treatment choices. Don’t miss this opportunity to “accelerate remission” and learn how to apply new science on BCMA platforms!

Upon completion of this activity, participants should be better able to:

  • Cite the safety and efficacy evidence supporting the use of established and emerging anti-BCMA platforms, including CAR-T and off-the-shelf antibody options, across several lines of therapy in MM
  • Integrate evidence-informed anti-BCMA platforms into customized sequential treatment plans for MM, including in early relapse and more heavily pretreated disease
  • Develop protocols to address practical aspects of anti-BCMA therapy, including planning for referral to specialized care, using appropriate bridging regimens, considering off-the-shelf antibody therapy, and understanding dosing and AE management

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the management of multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 22, 2024 - March 21, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Co-Chair & Presenter
Hans Lee, MD
Associate Professor, Department of Lymphoma/Myeloma
Director, Multiple Myeloma Clinical Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hans Lee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Support

This activity is supported through independent medical educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 22, 2024
Prof. Mohamad Mohty, MD, PhD/Christine N. Duncan, MD
Credits: 1.0 CME / NCPD
PVI, PeerView Institute for Medical Education
Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management

Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management

Start

Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management

Activity Description and Educational Objectives

Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) remains a major cause of morbidity and mortality for many individuals in the post-hematopoietic cell transplant (HCT) setting. Poor outcomes due to VOD are often driven by its variable onset and presentation complicating diagnosis; unchecked symptoms can lead to endothelial damage and, ultimately, to multiorgan dysfunction and failure. Recent evidence does show that modern, timely, team-based VOD management strategies can improve outcomes, but how can these protocols be adapted to fit real-world clinical practice and diverse patient populations?


In this activity recorded at the 2024 Tandem Meetings, leading transplant experts will provide learners with concise, high-level overviews of relevant science while sharing real-world cases in order to demonstrate modern principles of VOD prophylaxis and management. Throughout, the expert panel will cover topics such as: modern VOD prevention strategies, risk assessment, severity grading, and pharmacologic treatment, with an emphasis on collaborative care models in the post-transplant setting. Don’t miss this opportunity to get expert guidance, build your skillset, and work toward “canceling" the threat of VOD in HCT recipients.

Upon completion of this activity, participants should be better able to:

  • Cite risk factors for VOD/SOS, current evidence on prophylaxis, and markers of disease severity and multiorgan dysfunction/failure in adult and pediatric patients who are HCT candidates
  • Implement modern diagnostic and severity grading protocols in order to accurately capture and assess VOD/SOS in the post-HCT setting
  • Recommend evidence-based, timely treatment for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the care of patients with or at risk for VOD/SOS.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material

Release and Expiration Dates: March 21, 2024 - March 20, 2025

Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator

Prof. Mohamad Mohty, MD, PhD

Professor of Hematology

Hematology and Cellular Therapy Department

Saint-Antoine Hospital

Sorbonne University

Paris, France

Prof. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.

Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.

Co-Chair & Presenter

Christine N. Duncan, MD

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Medical Director of Clinical Research and Clinical Development, Gene Therapy Program, Boston Children’s Hospital

Associate Professor, Harvard Medical School

Boston, Massachusetts

Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.

Medical Director

Carmine DeLuca

PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.


No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.


The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management

Activity Description and Educational Objectives

Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) remains a major cause of morbidity and mortality for many individuals in the post-hematopoietic cell transplant (HCT) setting. Poor outcomes due to VOD are often driven by its variable onset and presentation complicating diagnosis; unchecked symptoms can lead to endothelial damage and, ultimately, to multiorgan dysfunction and failure. Recent evidence does show that modern, timely, team-based VOD management strategies can improve outcomes, but how can these protocols be adapted to fit real-world clinical practice and diverse patient populations?


In this activity recorded at the 2024 Tandem Meetings, leading transplant experts will provide learners with concise, high-level overviews of relevant science while sharing real-world cases in order to demonstrate modern principles of VOD prophylaxis and management. Throughout, the expert panel will cover topics such as: modern VOD prevention strategies, risk assessment, severity grading, and pharmacologic treatment, with an emphasis on collaborative care models in the post-transplant setting. Don’t miss this opportunity to get expert guidance, build your skillset, and work toward “canceling" the threat of VOD in HCT recipients.

Upon completion of this activity, participants should be better able to:

  • Cite risk factors for VOD/SOS, current evidence on prophylaxis, and markers of disease severity and multiorgan dysfunction/failure in adult and pediatric patients who are HCT candidates
  • Implement modern diagnostic and severity grading protocols in order to accurately capture and assess VOD/SOS in the post-HCT setting
  • Recommend evidence-based, timely treatment for adult and pediatric patients with VOD in the post-HCT setting, including supportive and pharmacologic measures

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the care of patients with or at risk for VOD/SOS.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material

Release and Expiration Dates: March 21, 2024 - March 20, 2025

Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator

Prof. Mohamad Mohty, MD, PhD

Professor of Hematology

Hematology and Cellular Therapy Department

Saint-Antoine Hospital

Sorbonne University

Paris, France

Prof. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.

Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.

Co-Chair & Presenter

Christine N. Duncan, MD

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Medical Director of Clinical Research and Clinical Development, Gene Therapy Program, Boston Children’s Hospital

Associate Professor, Harvard Medical School

Boston, Massachusetts

Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.

Medical Director

Carmine DeLuca

PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.


No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.


The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 21, 2024
Kathleen N. Moore, MD, MS
Credits: 1.25 CME / MOC / NCPD / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Start

Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Media: Enduring Material

Activity Release Date: March 18, 2024

Activity Expiration Date: April 17, 2025

Time to Complete Activity: 75 minutes

Activity Description

Which treatment advances are charting new standards of care for patients with endometrial or ovarian cancer? Use of immunotherapy-based approaches, ADCs, PARP inhibitors, and other innovative strategies have brought new hope for better outcomes in these gynecologic cancers, with many approvals and other strategies in late-stage development in a variety of settings.


Join PeerView, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancers for a new expert-led video designed to bring learners the latest evidence on approved and emerging treatment strategies and practical guidance on incorporating effective treatments, including via clinical trial enrollment, into patient care. Learn where approved and emerging treatments fit into therapeutic algorithms for ovarian and endometrial cancer, how companion diagnostics guide individualized treatment selection, and best practices for collaborative, team-based management of treatment-related adverse events. Participate now and help redefine optimal care for your patients.

Target Audience

This activity has been designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; obstetrician-gynecologists; advanced practice clinicians; nurses; and other healthcare professionals involved in the care of patients with endometrial or ovarian cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Review the rationale and efficacy and safety evidence for immunotherapy regimens, antibody-drug conjugates, PARP inhibitors, and other innovative approaches for patients with endometrial or ovarian cancer
  • Develop individualized therapeutic plans, including via clinical trial enrollment, utilizing the latest biomarker data and guideline-recommended treatment algorithms for eligible patients with endometrial or ovarian cancer
  • Implement collaborative, team-based strategies to mitigate and manage treatment-related AEs for patients with endometrial or ovarian cancer receiving modern therapeutic approaches, including use of immunotherapy, antibody-drug conjugates, and PARP inhibitors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Kathleen N. Moore, MD, MS

Deputy Director

Associate Director, Clinical Research

Virginia Kerley Cade Chair in Developmental Therapeutics

Co-Director, Cancer Therapeutics Program

Stephenson Cancer Center at the University of Oklahoma HSC

Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc; VBL Therapeutics; and Verastem, Inc.

Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Faculty/Planner

Floor J. Backes, MD

Professor

Fellowship Director

Director of Clinical Research

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

The Ohio State University College of Medicine

The James Cancer Hospital and Solove Research Institute

Columbus, Ohio

Floor J. Backes, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; BioNTech SE.; Clovis Oncology; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Myriad Genetics, Inc.

Grant/Research Support from AstraZeneca; Clovis Oncology; Eisai Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Natera, Inc.

Speaker for The GOG Foundation Inc.

Faculty/Planner

Bhavana Pothuri, MD, MS

Professor, Departments of Ob/Gyn and Medicine, NYU Grossman School of Medicine

Medical Director, Clinical Trials Office (CTO), Laura and Isaac Perlmutter Cancer Center

Director, Gynecologic Oncology Clinical Trials

New York, New York

Director, Diversity and Health Equity for Clinical Trials, GOG Foundation

Associate Clinical Trials Advisor, Ovarian and Endometrial Cancer, GOG Partners

Bhavana Pothuri, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Celsion Corporation/Immune Pharmaceuticals Inc.; I-MAB Biopharma Co., Ltd; InxMed; Merck & Co., Inc.; Mersana Therapeutics; Nuvation Bio, Inc.; Onconova Therapeutics; Sutro Biopharma, Inc.; Tesaro, Inc./GlaxoSmithKline; The GOG Foundation Inc; and Toray Group.

Grant/Research Support from Acrivon Therapeutics; Agenus Inc.; AstraZeneca; Celgene Corporation; Celsion Corporation/Immune Pharmaceuticals Inc.; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; Incyte; InxMed; Karyopharm Therapeutics; Merck & Co., Inc.; Novocure GmbH; NRG Oncology; Onconova Therapeutics; Seagen Inc.; Sutro Biopharma, Inc.; Takeda Pharmaceutical Company Limited; Tesaro, Inc./GlaxoSmithKline; Toray Group; VBL Therapeutics; and Xencor.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 4/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView


 

 

Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Media: Enduring Material

Activity Release Date: March 18, 2024

Activity Expiration Date: April 17, 2025

Time to Complete Activity: 75 minutes

Activity Description

Which treatment advances are charting new standards of care for patients with endometrial or ovarian cancer? Use of immunotherapy-based approaches, ADCs, PARP inhibitors, and other innovative strategies have brought new hope for better outcomes in these gynecologic cancers, with many approvals and other strategies in late-stage development in a variety of settings.


Join PeerView, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancers for a new expert-led video designed to bring learners the latest evidence on approved and emerging treatment strategies and practical guidance on incorporating effective treatments, including via clinical trial enrollment, into patient care. Learn where approved and emerging treatments fit into therapeutic algorithms for ovarian and endometrial cancer, how companion diagnostics guide individualized treatment selection, and best practices for collaborative, team-based management of treatment-related adverse events. Participate now and help redefine optimal care for your patients.

Target Audience

This activity has been designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; obstetrician-gynecologists; advanced practice clinicians; nurses; and other healthcare professionals involved in the care of patients with endometrial or ovarian cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Review the rationale and efficacy and safety evidence for immunotherapy regimens, antibody-drug conjugates, PARP inhibitors, and other innovative approaches for patients with endometrial or ovarian cancer
  • Develop individualized therapeutic plans, including via clinical trial enrollment, utilizing the latest biomarker data and guideline-recommended treatment algorithms for eligible patients with endometrial or ovarian cancer
  • Implement collaborative, team-based strategies to mitigate and manage treatment-related AEs for patients with endometrial or ovarian cancer receiving modern therapeutic approaches, including use of immunotherapy, antibody-drug conjugates, and PARP inhibitors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Kathleen N. Moore, MD, MS

Deputy Director

Associate Director, Clinical Research

Virginia Kerley Cade Chair in Developmental Therapeutics

Co-Director, Cancer Therapeutics Program

Stephenson Cancer Center at the University of Oklahoma HSC

Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc; VBL Therapeutics; and Verastem, Inc.

Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Faculty/Planner

Floor J. Backes, MD

Professor

Fellowship Director

Director of Clinical Research

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

The Ohio State University College of Medicine

The James Cancer Hospital and Solove Research Institute

Columbus, Ohio

Floor J. Backes, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; BioNTech SE.; Clovis Oncology; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Myriad Genetics, Inc.

Grant/Research Support from AstraZeneca; Clovis Oncology; Eisai Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Natera, Inc.

Speaker for The GOG Foundation Inc.

Faculty/Planner

Bhavana Pothuri, MD, MS

Professor, Departments of Ob/Gyn and Medicine, NYU Grossman School of Medicine

Medical Director, Clinical Trials Office (CTO), Laura and Isaac Perlmutter Cancer Center

Director, Gynecologic Oncology Clinical Trials

New York, New York

Director, Diversity and Health Equity for Clinical Trials, GOG Foundation

Associate Clinical Trials Advisor, Ovarian and Endometrial Cancer, GOG Partners

Bhavana Pothuri, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Celsion Corporation/Immune Pharmaceuticals Inc.; I-MAB Biopharma Co., Ltd; InxMed; Merck & Co., Inc.; Mersana Therapeutics; Nuvation Bio, Inc.; Onconova Therapeutics; Sutro Biopharma, Inc.; Tesaro, Inc./GlaxoSmithKline; The GOG Foundation Inc; and Toray Group.

Grant/Research Support from Acrivon Therapeutics; Agenus Inc.; AstraZeneca; Celgene Corporation; Celsion Corporation/Immune Pharmaceuticals Inc.; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; Incyte; InxMed; Karyopharm Therapeutics; Merck & Co., Inc.; Novocure GmbH; NRG Oncology; Onconova Therapeutics; Seagen Inc.; Sutro Biopharma, Inc.; Takeda Pharmaceutical Company Limited; Tesaro, Inc./GlaxoSmithKline; Toray Group; VBL Therapeutics; and Xencor.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 4/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView


 

 

March 18, 2024
Bradley J. Monk, MD, FACS, FACOG
Credits: 1.0 CME / MOC / NCPD / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

Start

Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

Media: Enduring Material

Activity Release Date: March 17, 2024

Activity Expiration Date: April 16, 2025

Time to Complete Activity: 60 minutes

Activity Description

As treatment of gynecologic malignancies moves beyond chemotherapy-based regimens, the use of antibody–drug conjugates (ADCs) has brought new hope to patients with cervical, endometrial, and ovarian cancers. With some of these agents already FDA approved and others advancing through clinical trials, clinicians have questions on how to incorporate ADCs into the personalized treatment of patients in a variety of settings.


In a new video-based activity developed by PeerView in collaboration with the National Ovarian Cancer Coalition (NOCC) and the Foundation for Women’s Cancer (FWC), a panel of experts combines foundational knowledge on the science supporting the use of ADCs in the treatment of gynecologic malignancies with discussion of patient cases drawn from their own practice to illustrate key decision points. Get insight on safety and efficacy evidence supporting approved and emerging ADCs and practical guidance on incorporating these agents into personalized treatment plans, including via clinical trial enrollment. Key topics include the role of biomarker testing in patient selection, team-based approaches for managing treatment-related adverse events, and educating patients to foster shared decision-making. Participate now to prepare for the future of gynecologic cancer care.

Target Audience

This activity has been designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; obstetrician-gynecologists; advanced practice clinicians; nurses; and other healthcare professionals involved in the management of patients with gynecologic cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the rationale for and accumulating safety/efficacy data supporting the use of ADCs in the treatment of gynecologic cancers
  • Integrate approved and emerging ADCs into personalized management plans for eligible patients with gynecologic cancers
  • Utilize patient education, evidence-based approaches, and collaborative management strategies to identify and address treatment-related adverse events associated with use of ADCs in patients with gynecologic cancers to ensure optimal outcomes

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Bradley J. Monk, MD, FACS, FACOG

Vice President and Member Board of Directors GOG-Foundation

Director GOG-Partners

Florida Cancer Specialists and Research Institute

Medical Director Late-Phase Clinical Research

West Palm Beach, Florida

Bradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Aadi Bioscience; Acrivon Therapeutics; Adaptimmune; Agenus Inc.; Alkermes; Amgen Inc.; AstraZeneca; Bayer; BioNTech SE; Clovis Oncology, Inc.; Corcept; Eisai Inc.; Elevar Therapeutics; EMD Merck; Genelux Corporation; Genmab A/S/Seagen Inc.; Gradalis, Inc.; ImmunoGen, Inc.; Karyopharm; Laekna Therapeutics; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure GmbH; OncoC4; Panavance Therapeutics Inc.; Pfizer Inc.; ProfoundBio; Regeneron Pharmaceuticals Inc.; Sarah Cannon; Tesaro Inc./GlaxoSmithKline; The GOG Foundation Inc; Tubulis GmbH; Verastem, Inc.; and Zentalis Pharmaceuticals.

Speaker for Aadi Bioscience; AstraZeneca; Clovis Oncology, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Genmab A/S/ Seagen Inc.; ImmunoGen, Inc.; Karyopharm; Merck & Co., Inc.; Myriad Genetics, Inc.; Tesaro Inc./GlaxoSmithKline; and The GOG Foundation Inc.

Faculty/Planner

Kathleen N. Moore, MD, MS

Deputy Director

Associate Director, Clinical Research

Virginia Kerley Cade Chair in Developmental Therapeutics

Co-Director, Cancer Therapeutics Program

Stephenson Cancer Center at the University of Oklahoma HSC

Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc; VBL Therapeutics; and Verastem, Inc.

Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Faculty/Planner

Ana Oaknin, MD, PhD

Head of Gynaecological Cancer Program

Medical Oncology Department

Vall d'Hebron University Hospital

Vall d'Hebron Institute of Oncology (VHIO)

Barcelona, Spain

Ana Oaknin, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Agenus Inc.; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera Pharmaceuticals; Eisai Co., Ltd.; EMD Serono; Exelisis, Inc.; F. Hoffmann-La Roche; Genmab A/S; GlaxoSmithKline; ImmunoGen, Inc.; iTeos Therapeutics; Merck Sharp & Dohme de Espana SA; Mersana Therapeutics; Novocure GmbH; OncXerna Therapeutics, Inc.; Pharma Mar SA; Regeneron Pharmaceuticals Inc.; Seagen, Inc.; Shattuck Labs, Inc.; and Sutro Biopharma, Inc.

Grant/Research Support from AbbVie Deutschland; Advaxis Inc.; Aeterna Zentaris; Amgen Inc.; Aprea Therapeutics AB; Bristol Myers Squibb; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche; ImmunoGen, Inc.; Merck Sharp & Dohme de Espana SA; Millennium Pharmaceuticals Inc.; Pharma Mar SA; Regeneron Pharmaceuticals Inc; and Tesaro.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 4/16/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

Media: Enduring Material

Activity Release Date: March 17, 2024

Activity Expiration Date: April 16, 2025

Time to Complete Activity: 60 minutes

Activity Description

As treatment of gynecologic malignancies moves beyond chemotherapy-based regimens, the use of antibody–drug conjugates (ADCs) has brought new hope to patients with cervical, endometrial, and ovarian cancers. With some of these agents already FDA approved and others advancing through clinical trials, clinicians have questions on how to incorporate ADCs into the personalized treatment of patients in a variety of settings.


In a new video-based activity developed by PeerView in collaboration with the National Ovarian Cancer Coalition (NOCC) and the Foundation for Women’s Cancer (FWC), a panel of experts combines foundational knowledge on the science supporting the use of ADCs in the treatment of gynecologic malignancies with discussion of patient cases drawn from their own practice to illustrate key decision points. Get insight on safety and efficacy evidence supporting approved and emerging ADCs and practical guidance on incorporating these agents into personalized treatment plans, including via clinical trial enrollment. Key topics include the role of biomarker testing in patient selection, team-based approaches for managing treatment-related adverse events, and educating patients to foster shared decision-making. Participate now to prepare for the future of gynecologic cancer care.

Target Audience

This activity has been designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; obstetrician-gynecologists; advanced practice clinicians; nurses; and other healthcare professionals involved in the management of patients with gynecologic cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the rationale for and accumulating safety/efficacy data supporting the use of ADCs in the treatment of gynecologic cancers
  • Integrate approved and emerging ADCs into personalized management plans for eligible patients with gynecologic cancers
  • Utilize patient education, evidence-based approaches, and collaborative management strategies to identify and address treatment-related adverse events associated with use of ADCs in patients with gynecologic cancers to ensure optimal outcomes

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Bradley J. Monk, MD, FACS, FACOG

Vice President and Member Board of Directors GOG-Foundation

Director GOG-Partners

Florida Cancer Specialists and Research Institute

Medical Director Late-Phase Clinical Research

West Palm Beach, Florida

Bradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Aadi Bioscience; Acrivon Therapeutics; Adaptimmune; Agenus Inc.; Alkermes; Amgen Inc.; AstraZeneca; Bayer; BioNTech SE; Clovis Oncology, Inc.; Corcept; Eisai Inc.; Elevar Therapeutics; EMD Merck; Genelux Corporation; Genmab A/S/Seagen Inc.; Gradalis, Inc.; ImmunoGen, Inc.; Karyopharm; Laekna Therapeutics; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure GmbH; OncoC4; Panavance Therapeutics Inc.; Pfizer Inc.; ProfoundBio; Regeneron Pharmaceuticals Inc.; Sarah Cannon; Tesaro Inc./GlaxoSmithKline; The GOG Foundation Inc; Tubulis GmbH; Verastem, Inc.; and Zentalis Pharmaceuticals.

Speaker for Aadi Bioscience; AstraZeneca; Clovis Oncology, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Genmab A/S/ Seagen Inc.; ImmunoGen, Inc.; Karyopharm; Merck & Co., Inc.; Myriad Genetics, Inc.; Tesaro Inc./GlaxoSmithKline; and The GOG Foundation Inc.

Faculty/Planner

Kathleen N. Moore, MD, MS

Deputy Director

Associate Director, Clinical Research

Virginia Kerley Cade Chair in Developmental Therapeutics

Co-Director, Cancer Therapeutics Program

Stephenson Cancer Center at the University of Oklahoma HSC

Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc; VBL Therapeutics; and Verastem, Inc.

Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Faculty/Planner

Ana Oaknin, MD, PhD

Head of Gynaecological Cancer Program

Medical Oncology Department

Vall d'Hebron University Hospital

Vall d'Hebron Institute of Oncology (VHIO)

Barcelona, Spain

Ana Oaknin, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Agenus Inc.; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera Pharmaceuticals; Eisai Co., Ltd.; EMD Serono; Exelisis, Inc.; F. Hoffmann-La Roche; Genmab A/S; GlaxoSmithKline; ImmunoGen, Inc.; iTeos Therapeutics; Merck Sharp & Dohme de Espana SA; Mersana Therapeutics; Novocure GmbH; OncXerna Therapeutics, Inc.; Pharma Mar SA; Regeneron Pharmaceuticals Inc.; Seagen, Inc.; Shattuck Labs, Inc.; and Sutro Biopharma, Inc.

Grant/Research Support from AbbVie Deutschland; Advaxis Inc.; Aeterna Zentaris; Amgen Inc.; Aprea Therapeutics AB; Bristol Myers Squibb; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche; ImmunoGen, Inc.; Merck Sharp & Dohme de Espana SA; Millennium Pharmaceuticals Inc.; Pharma Mar SA; Regeneron Pharmaceuticals Inc; and Tesaro.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 4/16/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 17, 2024
Amy Shapiro, MD
Credits: 1.0 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

Start

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

Media: Enduring Material
Activity Release Date: March 13, 2024
Activity Expiration Date: March 12, 2025
Time to Complete Activity: 60 minutes

Activity Description

While significant progress has been made in the management of severe hemophilia A (HA), the needs of those with mild and moderate HA, including females, have long been sidelined. Until now. Join two experts as they explore the latest evidence with available pharmacologic treatment options, including FVIII mimetics, that are paving the way for equitable HA care. Through interactive case discussions, the experts will provide collaborative solutions for overcoming challenges related to identifying, engaging, and managing individuals with severe and non-severe HA to ensure no one is left behind in the pursuit of equitable care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, fellows, residents, and other healthcare professionals involved in the care of patients with hemophilia A.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize unmet needs and barriers to equitable HA care, including among severe, nonsevere, and female HA populations
  • Summarize the evidence supporting established treatment options, including FVIII mimetic agents, with applications in diverse HA settings, including severe, nonsevere, and female HA populations
  • Develop individualized HA treatment plans with established therapeutics based on disease severity, inhibitor status, gender, and age, among other considerations
  • Employ principles of equitable, team-based, and participatory care when managing persons with HA, to ensure appropriate patient education, adherence counseling, and prompt management of disease- or treatment-related events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Amy Shapiro, MD
Medical Director and CEO
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana

Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.

Faculty/Planner
Maissaa Janbain, MD, MSCR
Associate Professor of Clinical Medicine
Director
Tulane University
Deming Department of Medicine
Section of Hematology & Medical Oncology - Louisiana Center for Bleeding & Clotting Disorders
New Orleans, Louisiana

Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/12/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

Media: Enduring Material
Activity Release Date: March 13, 2024
Activity Expiration Date: March 12, 2025
Time to Complete Activity: 60 minutes

Activity Description

While significant progress has been made in the management of severe hemophilia A (HA), the needs of those with mild and moderate HA, including females, have long been sidelined. Until now. Join two experts as they explore the latest evidence with available pharmacologic treatment options, including FVIII mimetics, that are paving the way for equitable HA care. Through interactive case discussions, the experts will provide collaborative solutions for overcoming challenges related to identifying, engaging, and managing individuals with severe and non-severe HA to ensure no one is left behind in the pursuit of equitable care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, fellows, residents, and other healthcare professionals involved in the care of patients with hemophilia A.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize unmet needs and barriers to equitable HA care, including among severe, nonsevere, and female HA populations
  • Summarize the evidence supporting established treatment options, including FVIII mimetic agents, with applications in diverse HA settings, including severe, nonsevere, and female HA populations
  • Develop individualized HA treatment plans with established therapeutics based on disease severity, inhibitor status, gender, and age, among other considerations
  • Employ principles of equitable, team-based, and participatory care when managing persons with HA, to ensure appropriate patient education, adherence counseling, and prompt management of disease- or treatment-related events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Amy Shapiro, MD
Medical Director and CEO
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana

Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.

Faculty/Planner
Maissaa Janbain, MD, MSCR
Associate Professor of Clinical Medicine
Director
Tulane University
Deming Department of Medicine
Section of Hematology & Medical Oncology - Louisiana Center for Bleeding & Clotting Disorders
New Orleans, Louisiana

Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/12/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 13, 2024
Hussein Tawbi, MD, PhD
Credits: 0.5 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

Start

Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

Media: Enduring Material

Activity Release Date: March 11, 2024

Activity Expiration Date: March 10, 2025

Time to Complete Activity: 30 minutes

Activity Description

Immunotherapy is now the centerpiece of modern, highly effective care for malignant melanoma. The most recent development in the immunotherapy revolution has centered on the validation of fixed-dose PD-1 and LAG-3 inhibitor combinations as an effective and safe frontline option for patients requiring treatment for advanced disease. This has raised a number of clinical questions related to the integration of PD-1/LAG-3 platforms into treatment plans (alongside other immune combinations) and the role of single-agent therapy.


This expert-led activity utilizes case-based teaching and short lectures to address these questions and provide guidance on incorporating the latest evidence on PD-1/LAG-3 therapy into practice, with the goal of illustrating the modern role of immune combinations in the frontline management of metastatic melanoma. The experts discuss how different baseline factors can inform treatment decisions made by the healthcare team, review the role of immunotherapy combinations in BRAF-mutant disease, and address practical aspects associated with the safe and effective delivery of dual checkpoint blockade with PD-1/LAG-3 platforms.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated guidelines and efficacy/safety evidence surrounding the use of newer immune-based approaches with PD-1/LAG-3 agents for unresectable and metastatic melanoma
  • Implement personalized treatment plans that include PD-1/LAG-3 combination therapies for unresectable and metastatic melanoma, including in BRAF-mutant or BRAF wild-type disease
  • Address practical aspects associated with newer dual checkpoint inhibition combinations, including irAE management and dosing, by working effectively in team-based care models

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Hussein Tawbi, MD, PhD

Deputy Chair and Professor

Department of Melanoma Medical Oncology

Co-Director, Andrew M. McDougall Brain Metastasis Clinic & Program

Melanoma Medical Oncology | Investigational Cancer Therapeutics

The University of Texas MD Anderson Cancer Center

Houston, Texas

Hussein Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Grant/Research Support from Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT Therapeutics. Research Support to Institution.

Faculty/Planner

Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS

Australian of the Year 2024

Co-Medical Director Melanoma Institute Australia

Professor of Melanoma Medical Oncology and Translational Research

Melanoma Institute Australia, The University of Sydney, and Royal North Shore & Mater Hospitals

Sydney, Australia

Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG (Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore; Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX B.V.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-035-H01-P

Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/10/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

Media: Enduring Material

Activity Release Date: March 11, 2024

Activity Expiration Date: March 10, 2025

Time to Complete Activity: 30 minutes

Activity Description

Immunotherapy is now the centerpiece of modern, highly effective care for malignant melanoma. The most recent development in the immunotherapy revolution has centered on the validation of fixed-dose PD-1 and LAG-3 inhibitor combinations as an effective and safe frontline option for patients requiring treatment for advanced disease. This has raised a number of clinical questions related to the integration of PD-1/LAG-3 platforms into treatment plans (alongside other immune combinations) and the role of single-agent therapy.


This expert-led activity utilizes case-based teaching and short lectures to address these questions and provide guidance on incorporating the latest evidence on PD-1/LAG-3 therapy into practice, with the goal of illustrating the modern role of immune combinations in the frontline management of metastatic melanoma. The experts discuss how different baseline factors can inform treatment decisions made by the healthcare team, review the role of immunotherapy combinations in BRAF-mutant disease, and address practical aspects associated with the safe and effective delivery of dual checkpoint blockade with PD-1/LAG-3 platforms.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated guidelines and efficacy/safety evidence surrounding the use of newer immune-based approaches with PD-1/LAG-3 agents for unresectable and metastatic melanoma
  • Implement personalized treatment plans that include PD-1/LAG-3 combination therapies for unresectable and metastatic melanoma, including in BRAF-mutant or BRAF wild-type disease
  • Address practical aspects associated with newer dual checkpoint inhibition combinations, including irAE management and dosing, by working effectively in team-based care models

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Hussein Tawbi, MD, PhD

Deputy Chair and Professor

Department of Melanoma Medical Oncology

Co-Director, Andrew M. McDougall Brain Metastasis Clinic & Program

Melanoma Medical Oncology | Investigational Cancer Therapeutics

The University of Texas MD Anderson Cancer Center

Houston, Texas

Hussein Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Grant/Research Support from Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT Therapeutics. Research Support to Institution.

Faculty/Planner

Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS

Australian of the Year 2024

Co-Medical Director Melanoma Institute Australia

Professor of Melanoma Medical Oncology and Translational Research

Melanoma Institute Australia, The University of Sydney, and Royal North Shore & Mater Hospitals

Sydney, Australia

Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG (Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore; Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX B.V.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-035-H01-P

Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/10/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 11, 2024
Prof. Laurence Albiges, MD, PhD
Credits: 0.5 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Start

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Media: Enduring Material

Activity Release Date: March 8, 2024

Activity Expiration Date: March 7, 2025

Time to Complete Activity: 30 minutes

Activity Description

In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
  • Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
  • Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Prof. Laurence Albiges, MD, PhD

Full Professor of Medical Oncology

Chair of Medical Oncology Department

Gustave Roussy Institute

Villejuif, France

Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-038-H01-P

Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Media: Enduring Material

Activity Release Date: March 8, 2024

Activity Expiration Date: March 7, 2025

Time to Complete Activity: 30 minutes

Activity Description

In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
  • Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
  • Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Prof. Laurence Albiges, MD, PhD

Full Professor of Medical Oncology

Chair of Medical Oncology Department

Gustave Roussy Institute

Villejuif, France

Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-038-H01-P

Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 08, 2024
Reshma L. Mahtani, DO
Credits: 1.0 CME / MOC / NCPD / IPCE
PVI, PeerView Institute for Medical Education
A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights

A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights

Start

 
 

A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights


 

Media: Enduring Material

    Activity Release Date: March 5, 2024

    Activity Expiration Date: March 4, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

HER2-targeting therapies are key components in the treatment of HER2-positive breast cancer. In this activity, a leading medical oncologist provides essential updates on the latest evidence and guideline recommendations for selecting and sequencing HER2-targeting therapies for HER2-positive metastatic breast cancer. In addition, real patient cases provide practical guidance for coordinating optimal breast cancer care across disciplines.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, pathologists, advanced practice providers, nurses, and other healthcare professionals involved in the care of patients with breast cancer.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Evaluate the characteristics, mechanisms of action, and latest safety and efficacy findings supporting the use of approved and emerging HER2-targeted therapies for HER2-positive MBC

  •    
  • Apply the latest evidence and guideline recommendations to optimally select and sequence HER2-targeting therapies for patients with HER2+ MBC, taking into account relevant treatment-, disease-, and patient-related factors

  •    
  • Collaborate with the members of the multidisciplinary and interprofessional team to develop individualized treatment plans for patients with HER2+ MBC, monitor and manage TRAEs, and engage patients as informed participants in their care

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Reshma L. Mahtani, DO

    Chief of Breast Medical Oncology

    Miami Cancer Institute

    Baptist Health South Florida

    Member, Memorial Sloan Kettering Cancer Alliance

    Miami, Florida


 

Reshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.

    Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights


 

Media: Enduring Material

    Activity Release Date: March 5, 2024

    Activity Expiration Date: March 4, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

HER2-targeting therapies are key components in the treatment of HER2-positive breast cancer. In this activity, a leading medical oncologist provides essential updates on the latest evidence and guideline recommendations for selecting and sequencing HER2-targeting therapies for HER2-positive metastatic breast cancer. In addition, real patient cases provide practical guidance for coordinating optimal breast cancer care across disciplines.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, pathologists, advanced practice providers, nurses, and other healthcare professionals involved in the care of patients with breast cancer.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Evaluate the characteristics, mechanisms of action, and latest safety and efficacy findings supporting the use of approved and emerging HER2-targeted therapies for HER2-positive MBC

  •    
  • Apply the latest evidence and guideline recommendations to optimally select and sequence HER2-targeting therapies for patients with HER2+ MBC, taking into account relevant treatment-, disease-, and patient-related factors

  •    
  • Collaborate with the members of the multidisciplinary and interprofessional team to develop individualized treatment plans for patients with HER2+ MBC, monitor and manage TRAEs, and engage patients as informed participants in their care

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Reshma L. Mahtani, DO

    Chief of Breast Medical Oncology

    Miami Cancer Institute

    Baptist Health South Florida

    Member, Memorial Sloan Kettering Cancer Alliance

    Miami, Florida


 

Reshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.

    Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


March 05, 2024
Alok A. Khorana, MD, FACP, FASCO
Credits: 0.75 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

Start

REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

Media: Enduring Material

Activity Release Date: March 1, 2024

Activity Expiration Date: February 28, 2025

Time to Complete Activity: 45 minutes

Activity Description

Venous thromboembolism (VTE), is a significant complication in cancer patients and a leading cause of mortality in this setting. Despite the availability of numerous guidelines and resources for cancer-associated VTE prevention and treatment, the uneven implementation of effective anticoagulation remains a barrier to highly effective management.


In this PeerView virtual activity, a leading expert on cancer-associated VTE will provide clinical insights and case-based guidance on current prevention and treatment strategies for cancer-associated VTE. Throughout, the faculty will address modern prophylactic and therapeutic anticoagulation options, underscore the importance of risk assessment and timely management, and offer insights into the selection of anticoagulants. Additionally, the expert will highlight the importance of an interprofessional team-based approach, aligned with shared decision-making, when caring for patients at risk of cancer-associated VTE.

Target Audience

This activity has been designed to meet the educational needs of oncologists, NPs, PAs, and other care team clinicians involved in the prevention and management of cancer-associated VTE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite recognized thromboembolic risk factors, guideline recommendations for modern risk assessment, and current evidence supporting modern anticoagulation strategies for cancer-associated VTE
  • Implement risk-adapted prophylaxis and treatment strategies for cancer-associated VTE while employing the principles of equitable, team-based, and participatory care
  • Manage practical aspects of VTE management in the cancer setting, including safe dosing and delivery of therapy, and provision of patient counseling on elevated VTE risks, adherence to treatment plans, and the risks/benefits of anticoagulation

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Alok A. Khorana, MD, FACP, FASCO

Sondra and Stephen Hardis Endowed Chair in Oncology Research

Vice-Chair, Taussig Cancer Center

Director, GI Malignancies Program

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Cleveland, Ohio

Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Anthos Therapeutics; Bayer Corporation; Bristol Myers Squibb; Pfizer; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/28/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

Media: Enduring Material

Activity Release Date: March 1, 2024

Activity Expiration Date: February 28, 2025

Time to Complete Activity: 45 minutes

Activity Description

Venous thromboembolism (VTE), is a significant complication in cancer patients and a leading cause of mortality in this setting. Despite the availability of numerous guidelines and resources for cancer-associated VTE prevention and treatment, the uneven implementation of effective anticoagulation remains a barrier to highly effective management.


In this PeerView virtual activity, a leading expert on cancer-associated VTE will provide clinical insights and case-based guidance on current prevention and treatment strategies for cancer-associated VTE. Throughout, the faculty will address modern prophylactic and therapeutic anticoagulation options, underscore the importance of risk assessment and timely management, and offer insights into the selection of anticoagulants. Additionally, the expert will highlight the importance of an interprofessional team-based approach, aligned with shared decision-making, when caring for patients at risk of cancer-associated VTE.

Target Audience

This activity has been designed to meet the educational needs of oncologists, NPs, PAs, and other care team clinicians involved in the prevention and management of cancer-associated VTE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite recognized thromboembolic risk factors, guideline recommendations for modern risk assessment, and current evidence supporting modern anticoagulation strategies for cancer-associated VTE
  • Implement risk-adapted prophylaxis and treatment strategies for cancer-associated VTE while employing the principles of equitable, team-based, and participatory care
  • Manage practical aspects of VTE management in the cancer setting, including safe dosing and delivery of therapy, and provision of patient counseling on elevated VTE risks, adherence to treatment plans, and the risks/benefits of anticoagulation

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Alok A. Khorana, MD, FACP, FASCO

Sondra and Stephen Hardis Endowed Chair in Oncology Research

Vice-Chair, Taussig Cancer Center

Director, GI Malignancies Program

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Cleveland, Ohio

Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Anthos Therapeutics; Bayer Corporation; Bristol Myers Squibb; Pfizer; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/28/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 01, 2024
Benjamin Levy, MD
Credits: 1.0 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Start

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Media: Enduring Material
Activity Release Date: February 24, 2024
Activity Expiration Date: March 23, 2025
Time to Complete Activity: 60 minutes

Activity Description

Antibody-drug conjugates (ADCs) represent an exciting frontier in the realm of precision lung cancer care, bringing hope to patients with limited treatment options. The promise of these agents is now transitioning from research settings to real-world practice, but many questions remain to be answered by ongoing studies. In addition to the first HER2-targeting ADC approved for HER2-mutated NSCLC, various other potent ADCs, such as those targeting HER3, TROP2, B7-H3, among many others, are showing promising activity in clinical trials, either as monotherapies or as integral parts of combinations, spanning different settings and patient populations.

This unique educational activity, based on a recent live symposium, features entertaining quiz-based Peer Pressure Challenges during which top experts are put on the spot to compete against each other and test their knowledge about ADCs. These game show segments are combined with related mini-lectures and open discussion forums to review key concepts related to the ADCs, analyze the latest evidence, examine unique nuances of using these therapies in real-world practice, and explore the challenging issues and burning questions about how to maximize the potential of ADCs in lung cancer.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other multidisciplinary and interprofessional healthcare providers involved in the care of patients with lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the clinical importance and biologic rationale for the use of different ADC-based approaches in lung cancer.
  • Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of various ADCs in lung cancer.
  • Integrate ADCs into treatment plans of carefully selected patients with lung cancer.
  • Follow best practices to identify and manage treatment-related adverse events in patients with lung cancer receiving ADC-based therapies with the entire care team to improve outcomes and quality of life.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Benjamin Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director, Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Medical Director, Thoracic Oncology Program, SKCC at Sibley
Washington, District of Columbia

Benjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Faculty/Planner
Marina Chiara Garassino, MD
Professor of Medicine
Director, Thoracic Oncology Program
University of Chicago Medicine
Hematology-Oncology
Chicago, Illinois

Marina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.
Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.

Faculty/Planner
Stephen V. Liu, MD
Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.

Faculty/Planner
Zosia Piotrowska, MD
Assistant Professor of Medicine, Harvard Medical School
Assistant in Medicine, Massachusetts General Hospital
Boston, Massachusetts

Zosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Media: Enduring Material
Activity Release Date: February 24, 2024
Activity Expiration Date: March 23, 2025
Time to Complete Activity: 60 minutes

Activity Description

Antibody-drug conjugates (ADCs) represent an exciting frontier in the realm of precision lung cancer care, bringing hope to patients with limited treatment options. The promise of these agents is now transitioning from research settings to real-world practice, but many questions remain to be answered by ongoing studies. In addition to the first HER2-targeting ADC approved for HER2-mutated NSCLC, various other potent ADCs, such as those targeting HER3, TROP2, B7-H3, among many others, are showing promising activity in clinical trials, either as monotherapies or as integral parts of combinations, spanning different settings and patient populations.

This unique educational activity, based on a recent live symposium, features entertaining quiz-based Peer Pressure Challenges during which top experts are put on the spot to compete against each other and test their knowledge about ADCs. These game show segments are combined with related mini-lectures and open discussion forums to review key concepts related to the ADCs, analyze the latest evidence, examine unique nuances of using these therapies in real-world practice, and explore the challenging issues and burning questions about how to maximize the potential of ADCs in lung cancer.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other multidisciplinary and interprofessional healthcare providers involved in the care of patients with lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the clinical importance and biologic rationale for the use of different ADC-based approaches in lung cancer.
  • Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of various ADCs in lung cancer.
  • Integrate ADCs into treatment plans of carefully selected patients with lung cancer.
  • Follow best practices to identify and manage treatment-related adverse events in patients with lung cancer receiving ADC-based therapies with the entire care team to improve outcomes and quality of life.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Benjamin Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director, Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Medical Director, Thoracic Oncology Program, SKCC at Sibley
Washington, District of Columbia

Benjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Faculty/Planner
Marina Chiara Garassino, MD
Professor of Medicine
Director, Thoracic Oncology Program
University of Chicago Medicine
Hematology-Oncology
Chicago, Illinois

Marina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.
Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.

Faculty/Planner
Stephen V. Liu, MD
Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.

Faculty/Planner
Zosia Piotrowska, MD
Assistant Professor of Medicine, Harvard Medical School
Assistant in Medicine, Massachusetts General Hospital
Boston, Massachusetts

Zosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

February 24, 2024
Taofeek K. Owonikoko, MD, PhD
Credits: 1.0 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Start

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Media: Enduring Material

Activity Release Date: February 24, 2024

Activity Expiration Date: March 23, 2025

Time to Complete Activity: 60 minutes

Activity Description

In recent years, there have been notable advances in the treatment of small-cell lung cancer (SCLC). Several new options have now become guideline-recommended standards of care. Despite these advancements, the prognosis for SCLC remains poor. This justifies efforts to optimize and expand the use of approved treatments and explore novel therapies with different mechanisms of action. Several potential therapeutic strategies are currently under examination in clinical trials that will hopefully lead to a further expansion of the SCLC treatment arsenal.


In this PeerView educational activity, based on a recent live symposium, experts discuss the latest evidence, ongoing trials, clinical cases, and challenging questions to take a deeper dive into the nuances of how to optimally integrate the latest therapeutic advances into clinical practice. The faculty panel provides evidence-based and practical guidance to help the lung cancer care team better understand the current and evolving treatment arsenal for SCLC and improve the care and outcomes of patients with SCLC.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other clinicians involved in the management of SCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Analyze the role and use of current and emerging therapies for SCLC, and the evidence that supports their use
  • Incorporate current standard-of-care therapies into individualized treatment plans for patients with SCLC based on the latest evidence, guideline recommendations, and patient needs and preferences
  • Recommend enrollment in clinical trials to eligible patients who could benefit from the current and emerging therapies
  • Implement multidisciplinary/interprofessional strategies and shared decision-making to ensure optimal care, including effective management of AEs, throughout the disease continuum for each patient with SCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Taofeek K. Owonikoko, MD, PhD

Executive Director, Marlene and Stewart Greenebaum Comprehensive Cancer Center

Marlene and Stewart Greenebaum Professor in Oncology

Senior Associate Dean of Cancer Programs, University of Maryland School of Medicine

Associate Vice President for Cancer Programs, University of Maryland, Baltimore

Chief of Service, University of Maryland Medical Center

Baltimore, Maryland

Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.

Faculty/Planner

Anne Chiang, MD, PhD, FASCO

Associate Professor of Medicine

Associate Yale Cancer Center Director, Clinical Initiatives

Yale University School of Medicine

New Haven, Connecticut

Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Faculty/Planner

Jared Weiss, MD

Professor of Medicine

Section Chief of Thoracic and Head/Neck Oncology

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina

Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.

Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Media: Enduring Material

Activity Release Date: February 24, 2024

Activity Expiration Date: March 23, 2025

Time to Complete Activity: 60 minutes

Activity Description

In recent years, there have been notable advances in the treatment of small-cell lung cancer (SCLC). Several new options have now become guideline-recommended standards of care. Despite these advancements, the prognosis for SCLC remains poor. This justifies efforts to optimize and expand the use of approved treatments and explore novel therapies with different mechanisms of action. Several potential therapeutic strategies are currently under examination in clinical trials that will hopefully lead to a further expansion of the SCLC treatment arsenal.


In this PeerView educational activity, based on a recent live symposium, experts discuss the latest evidence, ongoing trials, clinical cases, and challenging questions to take a deeper dive into the nuances of how to optimally integrate the latest therapeutic advances into clinical practice. The faculty panel provides evidence-based and practical guidance to help the lung cancer care team better understand the current and evolving treatment arsenal for SCLC and improve the care and outcomes of patients with SCLC.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other clinicians involved in the management of SCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Analyze the role and use of current and emerging therapies for SCLC, and the evidence that supports their use
  • Incorporate current standard-of-care therapies into individualized treatment plans for patients with SCLC based on the latest evidence, guideline recommendations, and patient needs and preferences
  • Recommend enrollment in clinical trials to eligible patients who could benefit from the current and emerging therapies
  • Implement multidisciplinary/interprofessional strategies and shared decision-making to ensure optimal care, including effective management of AEs, throughout the disease continuum for each patient with SCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Taofeek K. Owonikoko, MD, PhD

Executive Director, Marlene and Stewart Greenebaum Comprehensive Cancer Center

Marlene and Stewart Greenebaum Professor in Oncology

Senior Associate Dean of Cancer Programs, University of Maryland School of Medicine

Associate Vice President for Cancer Programs, University of Maryland, Baltimore

Chief of Service, University of Maryland Medical Center

Baltimore, Maryland

Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.

Faculty/Planner

Anne Chiang, MD, PhD, FASCO

Associate Professor of Medicine

Associate Yale Cancer Center Director, Clinical Initiatives

Yale University School of Medicine

New Haven, Connecticut

Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Faculty/Planner

Jared Weiss, MD

Professor of Medicine

Section Chief of Thoracic and Head/Neck Oncology

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina

Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.

Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

February 24, 2024
Credits: 1.0 CME / MOC / AAPA / IPCE
Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

Start

Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

Media: Enduring Material

Activity Release Date: February 21, 2024

Activity Expiration Date: March 20, 2025

Time to Complete Activity: 60 minutes

Activity Description

Multiple EGFR-targeted therapies have become available for patients with NSCLC harboring common and uncommon EGFR mutations, and novel options and combinations with practice-changing potential have shown great promise in clinical trials. How can healthcare providers make sense of the increasing complexity in the evidence base and best select and sequence the current and emerging therapy options?


In this PeerView educational activity, based on a recent live symposium, expert panelists provide guidance on appropriate biomarker testing, discuss the expanding landscape of targeted therapy options, and explore the nuances of making precision decisions for patients with EGFR-mutated NSCLC.

Target Audience

This activity has been designed to meet the educational needs of thoracic oncologists, medical oncologists, advanced practice clinicians, and other clinicians involved in the management of patients with lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the evolving role of EGFR mutations and co-occurring genomic alterations in guiding decision-making and treatment selection for patients with NSCLC
  • Apply broad NGS-based testing to identify therapeutically actionable alterations, including EGFR mutations, and potential resistance mechanisms
  • Integrate biomarker findings, clinical trial evidence, and shared decision-making strategies to personalize treatment planning in EGFRm NSCLC settings
  • Construct team-based strategies to ensure individualized care throughout the course of treatment, including patient/caregiver education and engagement, and optimal approaches to facilitate shared decision-making in EGFRm NSCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Joshua Sabari, MD

Assistant Professor of Medicine

NYU Langone Health

Perlmutter Cancer Center

New York, New York

Joshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.

Faculty/Planner

Jyoti D. Patel, MD

Professor of Medicine

Medical Director for Thoracic Oncology

Assistant Director for Clinical Research

Lurie Cancer Center

Associate Vice Chair of Clinical Research

Department of Medicine

Northwestern University, Feinberg School of Medicine

Chicago, Illinois

Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda Pharmaceutical Company Limited.

Other Financial or Material Support for Travel from Daiichi Sankyo, Inc. and Tempus.

Faculty/Planner

Alexander I. Spira, MD, PhD, FACP

Co Director Virginia Cancer Specialists Research Institute

Director, NEXT Oncology Virginia

Co Chair, US Oncology Thoracic Research Program

Fairfax, Virginia

Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.; AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte; Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.; Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio, Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics; Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines, Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda Pharmaceutical Company Limited.

Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.

Stock Shareholder in Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/20/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

Media: Enduring Material

Activity Release Date: February 21, 2024

Activity Expiration Date: March 20, 2025

Time to Complete Activity: 60 minutes

Activity Description

Multiple EGFR-targeted therapies have become available for patients with NSCLC harboring common and uncommon EGFR mutations, and novel options and combinations with practice-changing potential have shown great promise in clinical trials. How can healthcare providers make sense of the increasing complexity in the evidence base and best select and sequence the current and emerging therapy options?


In this PeerView educational activity, based on a recent live symposium, expert panelists provide guidance on appropriate biomarker testing, discuss the expanding landscape of targeted therapy options, and explore the nuances of making precision decisions for patients with EGFR-mutated NSCLC.

Target Audience

This activity has been designed to meet the educational needs of thoracic oncologists, medical oncologists, advanced practice clinicians, and other clinicians involved in the management of patients with lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the evolving role of EGFR mutations and co-occurring genomic alterations in guiding decision-making and treatment selection for patients with NSCLC
  • Apply broad NGS-based testing to identify therapeutically actionable alterations, including EGFR mutations, and potential resistance mechanisms
  • Integrate biomarker findings, clinical trial evidence, and shared decision-making strategies to personalize treatment planning in EGFRm NSCLC settings
  • Construct team-based strategies to ensure individualized care throughout the course of treatment, including patient/caregiver education and engagement, and optimal approaches to facilitate shared decision-making in EGFRm NSCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Joshua Sabari, MD

Assistant Professor of Medicine

NYU Langone Health

Perlmutter Cancer Center

New York, New York

Joshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.

Faculty/Planner

Jyoti D. Patel, MD

Professor of Medicine

Medical Director for Thoracic Oncology

Assistant Director for Clinical Research

Lurie Cancer Center

Associate Vice Chair of Clinical Research

Department of Medicine

Northwestern University, Feinberg School of Medicine

Chicago, Illinois

Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda Pharmaceutical Company Limited.

Other Financial or Material Support for Travel from Daiichi Sankyo, Inc. and Tempus.

Faculty/Planner

Alexander I. Spira, MD, PhD, FACP

Co Director Virginia Cancer Specialists Research Institute

Director, NEXT Oncology Virginia

Co Chair, US Oncology Thoracic Research Program

Fairfax, Virginia

Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.; AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte; Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.; Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio, Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics; Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines, Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda Pharmaceutical Company Limited.

Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.

Stock Shareholder in Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/20/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

February 21, 2024
Erin X. Barrett (Wei), MD/David Rosmarin, MD
Credits: 1.0 CME / MOC / NCPD / AAPA
PVI, PeerView Institute for Medical Education
Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care

Start

       
       

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care


       

Media: Enduring Material
Activity Release Date: February 7, 2024
Activity Expiration Date: February 6, 2025
Time to Complete Activity: 60 minutes

Activity Description

Bullous pemphigoid (BP) is a rare autoimmune subepidermal blistering disease characterized by large, tense blisters in the skin preceded by urticarial plaques and pruritus. It occurs most frequently in elderly patients, with risk rising exponentially after the age of 80. Diagnosis is often missed or delayed, partly due to it being a rare disorder, and partly due to atypical presentations or similarities with other skin conditions.

Although management guidelines have been updated there is still a lack of consensus on optimal treatment regimens and duration. Systemic corticosteroids and other immunosuppressive agents carry risks of adverse events; thus, targeted agents that are already approved for other diseases are under study for their utility in BP.

In order to help dermatologists and other clinicians treating patients with BP remain updated on advances in treatment, PeerView has prepared this discussion between two expert dermatologists. Learners will hear about the impact of BP on patient quality of life and how to differentiate BP from other skin conditions, as well as how to treat patients using the latest guidelines and targeted therapy.

Target Audience

This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers, and other clinicians who care for patients with bullous pemphigoid.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify and differentiate bullous pemphigoid (BP) from other skin conditions that can present similarly, based on current guidelines and expert recommendations
  • Discuss the impact of BP on elderly patients with regard to morbidity/mortality and quality of life, particularly for those with several comorbidities
  • Select and monitor treatment for patients with BP according to updated guidelines
  • Explain the rationale to improve outcomes for patients with BP through the use of targeted therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Erin X. Barrett (Wei), MD
Associate Professor of Dermatology
University of Nebraska Medical Center/Nebraska Medicine
Co-Director of the Bullous Disease Clinic
Director of Clinical Trials
Director of Inpatient Dermatology Services
Director of the Skin of Color/Ethnic Skin Dermatology Clinic
Omaha, Nebraska

Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
David Rosmarin, MD
Chair, Kampen-Norins Scholar
Indiana University
Indianapolis, Indiana

David Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/6/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   

       
       

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care


       

Media: Enduring Material
Activity Release Date: February 7, 2024
Activity Expiration Date: February 6, 2025
Time to Complete Activity: 60 minutes

Activity Description

Bullous pemphigoid (BP) is a rare autoimmune subepidermal blistering disease characterized by large, tense blisters in the skin preceded by urticarial plaques and pruritus. It occurs most frequently in elderly patients, with risk rising exponentially after the age of 80. Diagnosis is often missed or delayed, partly due to it being a rare disorder, and partly due to atypical presentations or similarities with other skin conditions.

Although management guidelines have been updated there is still a lack of consensus on optimal treatment regimens and duration. Systemic corticosteroids and other immunosuppressive agents carry risks of adverse events; thus, targeted agents that are already approved for other diseases are under study for their utility in BP.

In order to help dermatologists and other clinicians treating patients with BP remain updated on advances in treatment, PeerView has prepared this discussion between two expert dermatologists. Learners will hear about the impact of BP on patient quality of life and how to differentiate BP from other skin conditions, as well as how to treat patients using the latest guidelines and targeted therapy.

Target Audience

This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers, and other clinicians who care for patients with bullous pemphigoid.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify and differentiate bullous pemphigoid (BP) from other skin conditions that can present similarly, based on current guidelines and expert recommendations
  • Discuss the impact of BP on elderly patients with regard to morbidity/mortality and quality of life, particularly for those with several comorbidities
  • Select and monitor treatment for patients with BP according to updated guidelines
  • Explain the rationale to improve outcomes for patients with BP through the use of targeted therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Erin X. Barrett (Wei), MD
Associate Professor of Dermatology
University of Nebraska Medical Center/Nebraska Medicine
Co-Director of the Bullous Disease Clinic
Director of Clinical Trials
Director of Inpatient Dermatology Services
Director of the Skin of Color/Ethnic Skin Dermatology Clinic
Omaha, Nebraska

Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
David Rosmarin, MD
Chair, Kampen-Norins Scholar
Indiana University
Indianapolis, Indiana

David Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/6/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   
February 07, 2024
Matthew D. Galsky, MD
Credits: 1.50 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

Start

       
       

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum


       

Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 90 minutes

Activity Description

Which treatment advances are making an impact for patients with bladder cancer? Approved and emerging therapeutic strategies that include immune checkpoint inhibitors, antibody–drug conjugates (ADCs) and other classes of agents are changing outcomes for patients with locally advanced or metastatic disease, while those with earlier-stage disease, including non-muscle invasive bladder cancer (NMIBC) or high-risk muscle-invasive bladder cancer (MIBC), are benefiting from bladder-sparing and perioperative approaches. Join PeerView and the Bladder Cancer Advocacy Network (BCAN) to learn how these treatment advances translate into practice, as clinical decision points are brought to life through discussion of real-world patient cases. Featuring a panel of experts, as well as resources and tools from BCAN, this activity offers learners practical guidance on incorporating the latest data on a variety of therapeutic strategies into the development of personalized treatment plans for patients throughout the disease continuum, creating team-based protocols for managing adverse events, and addressing inequities in diagnosis and treatment to increase access to state-of-the-art care for all patients.

Target Audience

This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current data on therapeutic strategies based on innovative drug delivery techniques, targeted agents, and modern immunotherapy regimens for the treatment of bladder cancer
  • Integrate approved and emerging therapeutic approaches into personalized treatment plans for patients with various stages of bladder cancer, considering evidence, guidelines, and principles of team-based and patient-centered care
  • Implement evidence- and team-based management protocols to address the suite of adverse events associated with bladder cancer therapies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York

Matthew D. Galsky, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb and Merck & Co., Inc.

Faculty/Planner
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine of CWRU
Director, Genitourinary Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Shilpa Gupta, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics (Seagen Inc.).
Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.; and Seattle Genetics (Seagen Inc.).
Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle Genetics (Seagen Inc.).

Faculty/Planner
Andrea Necchi, MD
Associate Professor, Vita-Salute San Raffaele University
Director of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital
Milan, Italy

Andrea Necchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen Inc.
Grant/Research Support from  Bristol Myers Squibb; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement


                   
                       
                       
                   
               
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   

       
       

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum


       

Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 90 minutes

Activity Description

Which treatment advances are making an impact for patients with bladder cancer? Approved and emerging therapeutic strategies that include immune checkpoint inhibitors, antibody–drug conjugates (ADCs) and other classes of agents are changing outcomes for patients with locally advanced or metastatic disease, while those with earlier-stage disease, including non-muscle invasive bladder cancer (NMIBC) or high-risk muscle-invasive bladder cancer (MIBC), are benefiting from bladder-sparing and perioperative approaches. Join PeerView and the Bladder Cancer Advocacy Network (BCAN) to learn how these treatment advances translate into practice, as clinical decision points are brought to life through discussion of real-world patient cases. Featuring a panel of experts, as well as resources and tools from BCAN, this activity offers learners practical guidance on incorporating the latest data on a variety of therapeutic strategies into the development of personalized treatment plans for patients throughout the disease continuum, creating team-based protocols for managing adverse events, and addressing inequities in diagnosis and treatment to increase access to state-of-the-art care for all patients.

Target Audience

This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current data on therapeutic strategies based on innovative drug delivery techniques, targeted agents, and modern immunotherapy regimens for the treatment of bladder cancer
  • Integrate approved and emerging therapeutic approaches into personalized treatment plans for patients with various stages of bladder cancer, considering evidence, guidelines, and principles of team-based and patient-centered care
  • Implement evidence- and team-based management protocols to address the suite of adverse events associated with bladder cancer therapies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York

Matthew D. Galsky, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb and Merck & Co., Inc.

Faculty/Planner
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine of CWRU
Director, Genitourinary Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Shilpa Gupta, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics (Seagen Inc.).
Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.; and Seattle Genetics (Seagen Inc.).
Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle Genetics (Seagen Inc.).

Faculty/Planner
Andrea Necchi, MD
Associate Professor, Vita-Salute San Raffaele University
Director of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital
Milan, Italy

Andrea Necchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen Inc.
Grant/Research Support from  Bristol Myers Squibb; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement


                   
                       
                       
                   
               
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   
January 27, 2024
Lipika Goyal, MD, MPhil/Riad Salem, MD, MBA
Credits: 0.75 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum

Start

 
 

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum


 

Media: Enduring Material

    Activity Release Date: January 27, 2024

    Activity Expiration Date: February 26, 2025

    Time to Complete Activity: 45 minutes


 

Activity Description


 

Developments in treatment options for hepatocellular carcinoma (HCC), namely immune-based strategies, have enhanced outcomes across the disease continuum. To effectively integrate these modern regimens into practice, close collaboration among interventional radiologists (IR), medical oncologists, and the wider care team are critical. In this Clinical Consults activity, the expert faculty panel discuss patient scenarios illustrating real-world applications of current and emerging data and provide guidance on topics such as selecting and sequencing treatment over the course of disease, delivering personalized care when integrating immunotherapy platforms, and anticipating and managing safety/toxicity considerations.

   

    This activity unravels the latest data on innovative immunotherapy and locoregional therapy combinations in intermediate-stage disease and the transition to systemic therapy in advanced disease. Join today to learn what the experts have to say for synergizing success in HCC!


 

Target Audience


 

This activity has been designed to meet the educational needs of interventional radiologists, medical oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of HCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Discuss the latest safety/efficacy evidence and guideline recommendations supporting clinical applications of immunotherapy regimens for the management of early-, intermediate-, and advanced-stage HCC

  •    
  • Formulate personalized treatment plans with immunotherapy platforms for the management of HCC based on current and emerging clinical evidence, guideline recommendations, and expert guidance

  •    
  • Apply team-based strategies to address practical aspects of care when integrating immunotherapy platforms, including managing immune-related adverse events, dosing considerations, care coordination across specialties, and patient/caregiver education

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Co-Chair/Planner

    Lipika Goyal, MD, MPhil

    Director of Gastrointestinal Oncology

    Associate Professor of Medicine

    Division of Oncology

    Stanford School of Medicine

    Palo Alto, California


 

Lipika Goyal, MD, MPhil, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Alentis Therapeutics AG; Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.; Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera Biosciences.

    Data Safety Monitoring Board for AstraZeneca.

 


 

Co-Chair/Planner

    Riad Salem, MD, MBA

    Professor of Radiology, Medicine, and Surgery

    Chief, Section of Vascular and Interventional Radiology

    Vice-Chairman, Image-Guided Therapy

    Department of Radiology

    Northwestern University Feinberg School of Medicine

    Chicago, Illinois


 

Riad Salem, MD, MBA, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Bard Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai Inc./Merck & Co., Inc.; and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an independent educational grant from AstraZeneca.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum


 

Media: Enduring Material

    Activity Release Date: January 27, 2024

    Activity Expiration Date: February 26, 2025

    Time to Complete Activity: 45 minutes


 

Activity Description


 

Developments in treatment options for hepatocellular carcinoma (HCC), namely immune-based strategies, have enhanced outcomes across the disease continuum. To effectively integrate these modern regimens into practice, close collaboration among interventional radiologists (IR), medical oncologists, and the wider care team are critical. In this Clinical Consults activity, the expert faculty panel discuss patient scenarios illustrating real-world applications of current and emerging data and provide guidance on topics such as selecting and sequencing treatment over the course of disease, delivering personalized care when integrating immunotherapy platforms, and anticipating and managing safety/toxicity considerations.

   

    This activity unravels the latest data on innovative immunotherapy and locoregional therapy combinations in intermediate-stage disease and the transition to systemic therapy in advanced disease. Join today to learn what the experts have to say for synergizing success in HCC!


 

Target Audience


 

This activity has been designed to meet the educational needs of interventional radiologists, medical oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of HCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Discuss the latest safety/efficacy evidence and guideline recommendations supporting clinical applications of immunotherapy regimens for the management of early-, intermediate-, and advanced-stage HCC

  •    
  • Formulate personalized treatment plans with immunotherapy platforms for the management of HCC based on current and emerging clinical evidence, guideline recommendations, and expert guidance

  •    
  • Apply team-based strategies to address practical aspects of care when integrating immunotherapy platforms, including managing immune-related adverse events, dosing considerations, care coordination across specialties, and patient/caregiver education

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Co-Chair/Planner

    Lipika Goyal, MD, MPhil

    Director of Gastrointestinal Oncology

    Associate Professor of Medicine

    Division of Oncology

    Stanford School of Medicine

    Palo Alto, California


 

Lipika Goyal, MD, MPhil, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Alentis Therapeutics AG; Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.; Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera Biosciences.

    Data Safety Monitoring Board for AstraZeneca.

 


 

Co-Chair/Planner

    Riad Salem, MD, MBA

    Professor of Radiology, Medicine, and Surgery

    Chief, Section of Vascular and Interventional Radiology

    Vice-Chairman, Image-Guided Therapy

    Department of Radiology

    Northwestern University Feinberg School of Medicine

    Chicago, Illinois


 

Riad Salem, MD, MBA, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Bard Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai Inc./Merck & Co., Inc.; and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an independent educational grant from AstraZeneca.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 27, 2024
Sumanta Kumar Pal, MD, FASCO
Credits: 1.5 CME / MOC / NCPD / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies

Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies

Start

 
 

Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies


 

Media: Enduring Material

    Activity Release Date: January 26, 2024

    Activity Expiration Date: February 25, 2025

    Time to Complete Activity: 90 minutes


 

Activity Description


 

The rapid expansion in the renal cell carcinoma (RCC) therapeutic landscape has brought new hope for patients with kidney cancer along with increasing opportunities for healthcare professionals to provide personalized care across the disease spectrum. With FDA approvals of TKIs and immune checkpoint inhibitors in various disease settings, frontline treatment options include dual immunotherapy and IO plus TKI regimens, with some of these combinations showing benefit in patients with non–clear cell RCC, a population with limited clinical data and poor treatment outcomes. Critical therapeutic options are emerging in the perioperative setting, and further impact has been made in the refractory setting for patients who have been heavily pretreated.

   

    Join PeerView and the Kidney Cancer Research Alliance (KCCure) for an activity that features expert insights on the latest clinical trial and real-world evidence along with guidance on how to integrate scientific advances into modern RCC practice. Learn strategies for selecting and sequencing treatments, mitigating and managing adverse events, and incorporating shared decision-making into comprehensive, team-based care.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the management of RCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Review evidence on treatment efficacy and safety of approved and emerging therapeutic options for patients with RCC across different disease stages and histologic subtypes

  •    
  • Design individualized treatment plans based on current evidence, as well as patient-, disease-, and treatment-specific factors for patients with RCC

  •    
  • Develop team-based approaches to anticipate, mitigate, and manage adverse events associated with treatments for patients with RCC to promote optimal adherence, outcomes, and quality of life

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Sumanta Kumar Pal, MD, FASCO

    Professor, Department of Medical Oncology & Therapeutics Research

    Co-Director, Kidney Cancer Program

    City of Hope Comprehensive Cancer Center

    Duarte, California


 

Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or affiliation in the form of:

    Grant/Research Support from Allogene Therapeutics; CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.

 


 

Faculty/Planner

    Pedro C. Barata, MD, MSc, FACP

    Co-Leader Genitourinary (GU) Disease Team

    Director of GU Medical Oncology Research Program

    University Hospitals Seidman Cancer Center

    Associate Professor of Medicine

    Case Western Reserve University

    Case Comprehensive Cancer Center

    Cleveland, Ohio


 

Pedro C. Barata, MD, MSc, FACP, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Astellas Pharma Inc.; AVEO Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono; Eisai Co., Ltd.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Pfizer; and Sanofi.

    Grant/Research Support from EMD Serono and Exelixis, Inc.

    Speakers Bureau participant with Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; and Sanofi.

 


 

Faculty/Planner

    David F. McDermott, MD

    Chief, Medical Oncology

    Beth Israel Deaconess Medical Center

    Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program

    Professor of Medicine

    Harvard Medical School

    Boston, Massachusetts


 

David F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.


 

Faculty/Planner

    Tian Zhang, MD, MHS

    Associate Professor, Division of Hematology and Oncology

    Department of Internal Medicine

    UT Southwestern Medical Center

    Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas


 

Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Aravive; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer Corporation; Bristol Myers Squibb; Caris Life Sciences; Eisai Co., Ltd.; EMD Serono; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seagen Inc.

    Grant/Research Support from ALX Oncology; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and Tempus.

    Other Financial or Material Support for leadership or fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee; Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and National Cancer Institute (NCI) Steering Renal Task Force.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies


 

Media: Enduring Material

    Activity Release Date: January 26, 2024

    Activity Expiration Date: February 25, 2025

    Time to Complete Activity: 90 minutes


 

Activity Description


 

The rapid expansion in the renal cell carcinoma (RCC) therapeutic landscape has brought new hope for patients with kidney cancer along with increasing opportunities for healthcare professionals to provide personalized care across the disease spectrum. With FDA approvals of TKIs and immune checkpoint inhibitors in various disease settings, frontline treatment options include dual immunotherapy and IO plus TKI regimens, with some of these combinations showing benefit in patients with non–clear cell RCC, a population with limited clinical data and poor treatment outcomes. Critical therapeutic options are emerging in the perioperative setting, and further impact has been made in the refractory setting for patients who have been heavily pretreated.

   

    Join PeerView and the Kidney Cancer Research Alliance (KCCure) for an activity that features expert insights on the latest clinical trial and real-world evidence along with guidance on how to integrate scientific advances into modern RCC practice. Learn strategies for selecting and sequencing treatments, mitigating and managing adverse events, and incorporating shared decision-making into comprehensive, team-based care.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the management of RCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Review evidence on treatment efficacy and safety of approved and emerging therapeutic options for patients with RCC across different disease stages and histologic subtypes

  •    
  • Design individualized treatment plans based on current evidence, as well as patient-, disease-, and treatment-specific factors for patients with RCC

  •    
  • Develop team-based approaches to anticipate, mitigate, and manage adverse events associated with treatments for patients with RCC to promote optimal adherence, outcomes, and quality of life

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Sumanta Kumar Pal, MD, FASCO

    Professor, Department of Medical Oncology & Therapeutics Research

    Co-Director, Kidney Cancer Program

    City of Hope Comprehensive Cancer Center

    Duarte, California


 

Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or affiliation in the form of:

    Grant/Research Support from Allogene Therapeutics; CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.

 


 

Faculty/Planner

    Pedro C. Barata, MD, MSc, FACP

    Co-Leader Genitourinary (GU) Disease Team

    Director of GU Medical Oncology Research Program

    University Hospitals Seidman Cancer Center

    Associate Professor of Medicine

    Case Western Reserve University

    Case Comprehensive Cancer Center

    Cleveland, Ohio


 

Pedro C. Barata, MD, MSc, FACP, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Astellas Pharma Inc.; AVEO Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono; Eisai Co., Ltd.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Pfizer; and Sanofi.

    Grant/Research Support from EMD Serono and Exelixis, Inc.

    Speakers Bureau participant with Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; and Sanofi.

 


 

Faculty/Planner

    David F. McDermott, MD

    Chief, Medical Oncology

    Beth Israel Deaconess Medical Center

    Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program

    Professor of Medicine

    Harvard Medical School

    Boston, Massachusetts


 

David F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.


 

Faculty/Planner

    Tian Zhang, MD, MHS

    Associate Professor, Division of Hematology and Oncology

    Department of Internal Medicine

    UT Southwestern Medical Center

    Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas


 

Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Aravive; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer Corporation; Bristol Myers Squibb; Caris Life Sciences; Eisai Co., Ltd.; EMD Serono; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seagen Inc.

    Grant/Research Support from ALX Oncology; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and Tempus.

    Other Financial or Material Support for leadership or fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee; Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and National Cancer Institute (NCI) Steering Renal Task Force.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 26, 2024

Pages